Skip to main content
Premium Trial:

Request an Annual Quote

DxS' TheraScreen Gets Canadian OK

NEW YORK (GenomeWeb News) – DxS has received a license from Canadian regulatory authorities to sell its TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix), the UK-based firm said today.

In addition, Health Canada licensed the assay for broader use as a diagnostic for other anti-EGFR therapies beyond Vectibix.

DxS said that approximately 60 percent of metastatic colorectal cancer patients have a non-mutated KRAS gene, and studies have shown that patients with this particular marker may respond to Vectibix therapy.

Under a previously signed deal, Roche Diagnostics will distribute and support sales of the TheraScreen: K-RAS Mutation Kit in Canada beginning next month.